Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2542314rdf:typepubmed:Citationlld:pubmed
pubmed-article:2542314lifeskim:mentionsumls-concept:C0001675lld:lifeskim
pubmed-article:2542314lifeskim:mentionsumls-concept:C0010453lld:lifeskim
pubmed-article:2542314lifeskim:mentionsumls-concept:C0034721lld:lifeskim
pubmed-article:2542314lifeskim:mentionsumls-concept:C0034693lld:lifeskim
pubmed-article:2542314lifeskim:mentionsumls-concept:C0001924lld:lifeskim
pubmed-article:2542314lifeskim:mentionsumls-concept:C0227525lld:lifeskim
pubmed-article:2542314lifeskim:mentionsumls-concept:C0009325lld:lifeskim
pubmed-article:2542314lifeskim:mentionsumls-concept:C1705480lld:lifeskim
pubmed-article:2542314lifeskim:mentionsumls-concept:C0017262lld:lifeskim
pubmed-article:2542314lifeskim:mentionsumls-concept:C0205225lld:lifeskim
pubmed-article:2542314pubmed:issue16lld:pubmed
pubmed-article:2542314pubmed:dateCreated1989-7-5lld:pubmed
pubmed-article:2542314pubmed:abstractTextThe mechanisms that regulate collagen gene expression in hepatic cells are poorly understood. Accelerated Ca2+ fluxes are associated with inhibiting collagen synthesis selectively in human fibroblasts (Flaherty, M., and Chojkier, M. (1986) J. Biol. Chem. 261, 12060-12065). In suspension cultures of isolated hepatocytes, the Ca2+ agonist vasopressin increases cytosolic levels of free Ca2+ (Thomas, A.P., Marks, J.S., Coll, K.E., and Williamson, J. R. (1983) J. Biol. Chem. 258, 5716-5725). However, whether vasopressin's interactions with plasma membrane V1 receptors attenuate hepatic collagen production is unknown. We investigated this problem by studying vasopressin's effects on collagen synthesis and Ca2+ efflux in long-term primary cultures of differentiated and proliferation-competent adult rat hepatocytes. Twelve-day-old quiescent cultures were exposed to test substances and labeled with [5-3H]proline. Determinations of radioactivity in collagenase-sensitive and collagenase-resistant proteins were used to calculate the relative levels of collagen production. Synthetic [8-arg]vasopressin stimulated 45Ca2+ efflux within 1 min and inhibited hepatocyte collagen production within 3 h by 50%; overall rates of protein synthesis were not affected significantly. In cultures labeled with [35S]methionine, vasopressin also decreased the levels of newly synthesized and secreted albumin, but not fibrinogen, detected in specific immunoprecipitates analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and autoradiography. Northern blot analyses using specific [32P]cDNA probes revealed 70% decreases in hybridizable levels of collagen alpha 1(I) mRNA in hepatocyte cultures treated with either vasopressin or Ca2+ ionophore A23187; hybridizable levels of albumin mRNA also fell approximately 50% following vasopressin treatment. Vasopressin did not affect collagen production in quiescent cultures of mouse Swiss 3T3, human myofibroblast or rat smooth muscle cells; and hepatocyte collagen production was unaffected by treatment with glucagon or dibutyryl cAMP. Thus, accelerated Ca2+ fluxes induced by vasopressin are associated with decreased production of hepatocyte collagen and albumin in primary cultures that simulate quiescent adult rat liver.lld:pubmed
pubmed-article:2542314pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2542314pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2542314pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2542314pubmed:languageenglld:pubmed
pubmed-article:2542314pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2542314pubmed:citationSubsetIMlld:pubmed
pubmed-article:2542314pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2542314pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2542314pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2542314pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2542314pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2542314pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2542314pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2542314pubmed:statusMEDLINElld:pubmed
pubmed-article:2542314pubmed:monthJunlld:pubmed
pubmed-article:2542314pubmed:issn0021-9258lld:pubmed
pubmed-article:2542314pubmed:authorpubmed-author:LeffertH LHLlld:pubmed
pubmed-article:2542314pubmed:authorpubmed-author:ChojkierMMlld:pubmed
pubmed-article:2542314pubmed:authorpubmed-author:BrennerD ADAlld:pubmed
pubmed-article:2542314pubmed:issnTypePrintlld:pubmed
pubmed-article:2542314pubmed:day5lld:pubmed
pubmed-article:2542314pubmed:volume264lld:pubmed
pubmed-article:2542314pubmed:ownerNLMlld:pubmed
pubmed-article:2542314pubmed:authorsCompleteYlld:pubmed
pubmed-article:2542314pubmed:pagination9583-91lld:pubmed
pubmed-article:2542314pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:2542314pubmed:meshHeadingpubmed-meshheading:2542314-...lld:pubmed
pubmed-article:2542314pubmed:meshHeadingpubmed-meshheading:2542314-...lld:pubmed
pubmed-article:2542314pubmed:meshHeadingpubmed-meshheading:2542314-...lld:pubmed
pubmed-article:2542314pubmed:meshHeadingpubmed-meshheading:2542314-...lld:pubmed
pubmed-article:2542314pubmed:meshHeadingpubmed-meshheading:2542314-...lld:pubmed
pubmed-article:2542314pubmed:meshHeadingpubmed-meshheading:2542314-...lld:pubmed
pubmed-article:2542314pubmed:meshHeadingpubmed-meshheading:2542314-...lld:pubmed
pubmed-article:2542314pubmed:meshHeadingpubmed-meshheading:2542314-...lld:pubmed
pubmed-article:2542314pubmed:meshHeadingpubmed-meshheading:2542314-...lld:pubmed
pubmed-article:2542314pubmed:meshHeadingpubmed-meshheading:2542314-...lld:pubmed
pubmed-article:2542314pubmed:meshHeadingpubmed-meshheading:2542314-...lld:pubmed
pubmed-article:2542314pubmed:meshHeadingpubmed-meshheading:2542314-...lld:pubmed
pubmed-article:2542314pubmed:meshHeadingpubmed-meshheading:2542314-...lld:pubmed
pubmed-article:2542314pubmed:meshHeadingpubmed-meshheading:2542314-...lld:pubmed
pubmed-article:2542314pubmed:meshHeadingpubmed-meshheading:2542314-...lld:pubmed
pubmed-article:2542314pubmed:meshHeadingpubmed-meshheading:2542314-...lld:pubmed
pubmed-article:2542314pubmed:year1989lld:pubmed
pubmed-article:2542314pubmed:articleTitleVasopressin inhibits type-I collagen and albumin gene expression in primary cultures of adult rat hepatocytes.lld:pubmed
pubmed-article:2542314pubmed:affiliationDepartment of Medicine, Veterans Administration Medical Center, San Diego, California.lld:pubmed
pubmed-article:2542314pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:2542314pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:2542314pubmed:publicationTypeResearch Support, U.S. Gov't, Non-P.H.S.lld:pubmed
pubmed-article:2542314pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2542314lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2542314lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2542314lld:pubmed